Compare Boston Scientific Corporation (BSX) vs Caesars Entertainment Inc (CZR) Price & Performance

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Caesars Entertainment (CZR) trades at $29.62, down 1.5% on the day, with a bearish technical signal and recent quarterly earnings misses. The company reported a Q2 2026 loss of $0.30 per share, missing estimates, but revenue of $3.0 billion topped expectations. Fundamentals show a negative net income margin of -3.99% and high long-term debt of $12.03 billion, though operating cash flow remains strong at $1.30 billion in 2025. The pending acquisition by Tilman Fertitta for approximately $17.6 billion is a key development, as reported by the Wall Street Journal on July 28, 2026.

CZR presents a mixed outlook with acquisition potential offset by persistent losses and debt. The stock's low P/S ratio of 0.52 offers value, but investors face risks from earnings volatility and competitive pressures in the leisure sector. Analyst sentiment is cautious with 70% hold ratings, reflecting uncertainty around profitability improvements and integration post-acquisition.